natgillin/translations-raw huggingface dataset:
The concurrent use of a formulation of prolonged-release and immediate-release exenatide has not been studied and is not recommended. 
Sočasne uporabe eksenatida v obliki s podaljšanim sproščanjem in eksenatida v obliki s takojšnim sproščanjem niso preučevali in se ne priporoča.
To get a full dose, the medicine must be mixed well and look cloudy. 
Da boste prejeli celotni odmerek, mora biti zdravilo dobro premešano in mora biti na pogled motno.
Treatment with prolonged-release exenatide and dapagliflozin combination at Week 28 resulted in a significant mean change reduction of -4.3±0.8 mmHg in systolic blood pressure compared to prolonged-release exenatide alone of -1.2±0.8 mmHg (p<0.01) or to dapagliflozin alone of -1.8±0.8 mmHg (p<0.05). 
Zdravljenje s kombinacijo eksenatida v obliki s podaljšanim sproščanjem in dapagliflozina je v 28. tednu doseglo značilno znižanje povprečnega sistoličnega krvnega tlaka za -4,3±0,8 mmHg v primerjavi z -1,2±0,8 mmHg (p< 0,01) za eksenatid v obliki s podaljšanim sproščanjem, uporabljen samostojno in -1,8±0,8 mmHg (p< 0,05) za dapagliflozin, uporabljen samostojno.
Sulphonylureas 
Sulfonilsečnine
DO NOT proceed unless needle is attached 
NE NADALJUJTE, dokler igla ni nameščena
Table 1: Adverse reactions of prolonged-release exenatide identified from clinical studies and spontaneous reports 
Preglednica 1: Neželeni učinki eksenatida v obliki s podaljšanim sproščanjem, ugotovljeni v kliničnih študijah in na podlagi spontanih poročil
Plunger not lining up with black dashed Dose Line Being unable to push the plunger down when injecting 
Odstranitev pokrovčka iz igle Bat ni poravnan s črno odmerno črto Bata ob injiciranju ni možno potisniti navzdol
If you miss a dose and there are only 1 or 2 days until your next dose is due, skip the missed dose and take the next one as usual, on the day it is due. 
Če izpustite odmerek in sta do naslednjega odmerka le še 1 ali 2 dneva, preskočite pozabljeni odmerek in uporabite naslednjega kot po navadi, na dan, ko je na vrsti.
Do not sell separately. 
Ločena prodaja ni dovoljena.
Following weekly administration of 2 mg Bydureon BCise, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/ml) in 2 weeks with gradual increase in the average plasma exenatide concentration up to Week 8. 
Ob tedenskem dajanju 2 mg zdravila Bydureon BCise je povprečna koncentracija eksenatida v dveh tednih presegla minimalno učinkovito koncentracijo (~ 50 pg/ml), s postopnim povečevanjem povprečne plazemske koncentracije eksenatida do 8. tedna.
Other medicines and Bydureon Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, particularly: - other medicines that are used to treat type 2 diabetes, such as medicines that work like Bydureon (for example: liraglutide or other exenatide containing products, as taking these medicines with Bydureon is not recommended. 
Druga zdravila in zdravilo Bydureon Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, še zlasti: - druga zdravila za zdravljenje sladkorne bolezni tipa 2, na primer zdravila, ki delujejo podobno kot zdravilo Bydureon (npr. liraglutid ali druga zdravila, ki vsebujejo eksenatid), ker uporaba teh zdravil skupaj z zdravilom Bydureon ni priporočljiva.
When prolonged-release exenatide is used in combination with a sulphonylurea, patients should be advised to take precautions to avoid hypoglycaemia while driving and using machines. 
Kadar eksenatid v obliki s podaljšanim sproščanjem uporabljamo v kombinaciji s sulfonilsečnino, moramo bolnikom svetovati o previdnostnih ukrepih, da bi se med vožnjo in upravljanjem strojev izognili hipoglikemiji.
Hold the pen up to the light and look through both sides of the mixing window. 
Peresnik držite pokonci proti svetlobi in poglejte skozi obe strani okenca za mešanje.
You should inject this medicine immediately after mixing the suspension. 
To zdravilo si morate po mešanju suspenzije takoj injicirati.
However, after you unlock it, you must complete the preparation steps right away and inject to get the full dose. 
Toda ko ga odklenete, morate takoj opraviti korake za pripravo in zdravilo injicirati, da boste dobili celoten odmerek.
Mixed Well 
Dobro premešano
Approximately 49.3% had mild renal impairment (estimated glomerular filtration rate [eGFR] ≥60 to ≤89 mL/min/1.73 m2) and 21.6% had moderate renal impairment (eGFR 
Približno 49,3 % bolnikov je imelo blago okvaro ledvic (ocenjena hitrost glomerularne filtracije [eGFR] ≥ 60 do ≤ 89 ml/min/1,73 m2) in 21,6 % jih je imelo zmerno okvaro ledvic (eGFR ≥ 30 do ≤ 59 ml/min/1,73 m2).
Small subcutaneous injection site nodules were observed very frequently in clinical studies, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations. 
V kliničnih študijah so se na mestu injiciranja zelo pogosto pojavili majhni podkožni noduli, kar je skladno z znanimi lastnostmi poli (D,L-laktid koglikolid) polimernih mikrosfernih formulacij.
Treatment with prolonged-release exenatide persistently significantly improved glycaemic control and weight control, compared to the insulin glargine treatment. 
Zdravljenje z eksenatidom v obliki s podaljšanim sproščanjem je trajno izboljšalo urejenost glikemije in nadzorovanje telesne mase, v primerjavi z zdravljenjem z insulinom glarginom.
The two chambers are separated by a second chlorobutyl rubber piston. 
Prekata med seboj loči drugi bat iz klorobutilne gume.
Event Rate n (%) 
Delež dogodkov n (%)
Use a puncture-resistant container to throw away the pen with the needle still attached. 
Uporabite vsebnik, odporen proti prebadanju, da boste zavrgli peresnik, na katerem je še vedno nameščena igla.
Follow the “Instructions for the User” provided in the carton to inject Bydureon BCise 
Sledite “Navodilom za uporabnika”, ki se nahajajo v škatli, za injiciranje zdravila Bydureon BCise.
Includes acute renal failure, worsened chronic renal failure, renal impairment, increased serum creatinine. 
Vključuje akutno odpoved ledvic, poslabšanje kronične odpovedi ledvic, okvaro ledvic, zvišanje kreatinina v serumu.
• The pen must be stored flat. 
• Peresnik je treba shranjevati v vodoravnem položaju.
If not mixed well, continue to shake hard. 
Če zdravilo ni dobro premešano, ga še naprej močno pretresajte.
Thyroid tumours have been observed in rats and mice with long acting GLP-1 receptor agonists. 
Pri podganah in miših so ob dolgodelujočih agonistih receptorjev GLP-1 opažali tumorje ščitnice.
Slowly push in the plunger so the top of the plunger lines up with the black dashed Dose Line. 
Počasi pritisnite bat tako, da bo vrh bata poravnan s črno odmerno črto.
Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety. 
Ugotovili so, da uporaba eksenatida zaradi zmanjšanega apetita in povečanega občutka sitosti zmanjša vnos hrane.
Hepatic impairment No dose adjustment is necessary for patients with hepatic impairment (see section 5.2). 
Okvara jeter Pri bolnikih z okvaro jeter odmerka ni potrebno prilagajati (glejte poglavje 5.2).
At the study endpoint, approximately 43% of patients had low titre antibodies to exenatide and 14% of patients had high titre antibodies. 
Ob koncu študije je imelo nizke titre protiteles proti eksenatidu približno 43 % bolnikov in visoke titre 14 % bolnikov.
In a single-dose pharmacokinetic study of immediate-release exenatide in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5 mcg) resulted in slightly lower mean AUC (16% lower) and Cmax (25% lower) compared to those observed in adults. 
V farmakokinetični študiji z eksenatidom v obliki s takojšnim sproščanjem pri 13 bolnikih z diabetesom tipa 2, starih med 12 in 16 let, je dajanje eksenatida (5 g) rahlo znižalo povprečno vrednost AUC (16 % nižja) in Cmax (25 % nižja) v primerjavi z vrednostmi, ki so jih opazili pri odraslih.
One needle is a spare. 
Ena igla je dodatna.
There is a spare needle in case you need it. 
Imate tudi dodatno iglo, v kolikor bi jo potrebovali.
You can inject each dose of the medicine in your stomach area (abdomen), your thigh, or the back of your upper arm. 
Vsak odmerek si lahko injicirate v področje trebuha (abdomna), stegna ali zadnjega dela nadlakti.
Insulin glargine was dosed targeting a fasting plasma glucose of 4.0 to 5.5 mmol/l (72 to 99 mg/dl). 
Odmerek insulina glargina je bil določen s ciljno koncentracijo glukoze v plazmi na tešče od 4,0 do 5,5 mmol/l (72 do 99 mg/dl).
The solution should have NO CLUMPS and be uniformly cloudy. 
V raztopini NE SME BITI GRUDIC in biti mora enakomerno motna.
Review the Instructions for the User Step 3 to confirm the order of operations, then contact the local representative of the Marketing Authorisation Holder (see section 6 of the Package Leaflet for a list of contacts by country). 
Ponovno preglejte 3. korak v navodilih za uporabnika, da boste preverili zaporedje operacij, nato se obrnite na lokalnega predstavnika imetnika dovoljenja za promet z zdravilom (glejte poglavje 6 v navodilu za uporabo za seznam kontaktnih podatkov po državah).
A study of 26-week duration has been conducted, in which prolonged-release exenatide 2 mg is compared to insulin glargine once daily. 
V 26-tedenski študiji so primerjali 2 mg eksenatida v obliki s podaljšanim sproščanjem z insulinom glarginom enkrat dnevno.
Warnings and precautions Talk to your doctor, pharmacist, or diabetes nurse before using Bydureon about the following: - If you use this medicine in combination with a sulphonylurea, as low blood sugar (hypoglycaemia) can occur. 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Bydureon se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro v diabetološki ambulanti o naslednjem: - Če uporabljate to zdravilo v kombinaciji s sulfonilsečnino, ker lahko pride do nizkega sladkorja v krvi (hipoglikemije).
Where to learn more about Bydureon 
Kje se lahko izve več o zdravilu Bydureon
This is to make sure you get the full dose. 
Tako boste zagotovili, da boste dobili celoten odmerek.
- The other ingredients are: poly (D,L-lactide-co-glycolide), sucrose and medium chain triglyceride. 
- Druge sestavine zdravila so: poli (D,L-laktid koglikolid), saharoza in srednjeverižni triglicerid.
For prolonged-release exenatide treated patients, the incidence of potentially immunogenic injection site reactions (most commonly pruritus with or without erythema) during the 30-week and the two 26-week studies was 9%. 
Incidenca možno imunogenih reakcij na mestu injiciranja (najpogosteje pruritis z ali brez eritrema) pri bolnikih, zdravljenih z eksenatidom v obliki s podaljšanim sproščanjem, je bila v 30-tedenski in dveh 26-tedenskih študijah 9 %.
Based on hypoglycaemic events that have symptoms consistent with hypoglycaemia with a concomitant glucose value of <54 mg/dl (3 mmol/l) prior to treatment. 
Na podlagi hipoglikemij, ki imajo simptome, značilne za hipoglikemijo, ter jih ob tem spremlja koncentracija glukoze pred zdravljenjem < 54 mg/dl (3 mmol/l).
In a 28-week open-label study (oral medication-blinded), Bydureon BCise was compared to sitagliptin and placebo in subjects also using metformin ≥ 1,500 mg daily. 
V odprti 28-tedenski študiji (slepljeni za peroralno zdravljenje) so zdravilo Bydureon BCise primerjali s sitagliptinom in placebom pri preiskovancih, ki so uporabljali tudi ≥ 1.500 mg metformina na dan.
If you use more of this medicine than you should, please consult your doctor first as you may need medical treatment. 
Če ste uporabili večji odmerek zdravila Bydureon, kot bi smeli Če ste uporabili več tega zdravila, kot bi smeli, se o tem najprej posvetujte z zdravnikom, saj boste morda potrebovali zdravljenje.
Prior to use of the pen, it is recommended that you should be trained by a doctor or diabetes nurse on its proper use. 
Priporočljivo je, da vas pred uporabo peresnika zdravnik ali medicinska sestra v diabetološki ambulanti nauči njegove pravilne uporabe.
Common questions and answers. 
Pogosta vprašanja in odgovori.
When added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be considered to reduce the risk of hypoglycaemia (see section 4.4). 
Kadar dodamo zdravljenju s sulfonilsečnino, moramo premisliti o zmanjšanju odmerka sulfonilsečnine, da zmanjšamo tveganje za pojav hipoglikemije (glejte poglavje 4.4).
This reduction in body weight was seen irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction of -1.9 kg to -5.2 kg with nausea versus -1.0 kg to -2.9 kg without nausea). 
To znižanje telesne mase pri bolnikih je bilo neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (povprečno znižanje -1,9 kg do -5,2 kg z navzeo proti -1,0 kg do -2,9 kg brez navzee).
Place the needle, vial connector package, vial, and syringe on a clean, flat surface. 
Iglo, paket s povezovalcem viale, vialo in injekcijsko brizgo postavite na čisto, ravno površino.
Subcutaneous injection site nodules were observed frequently in clinical studies, consistent with the known properties of poly (D,L-lactide co-glycolide) polymer microsphere formulations. 
V kliničnih študijah so se na mestu injiciranja pogosto pojavili podkožni noduli, kar je skladno z znanimi lastnostmi poli (D,L-laktid koglikolid) polimernih mikrosfernih formulacij.
There have been uncommon events of altered renal function with exenatide, including increased serum creatinine, renal impairment, worsened chronic renal failure and acute renal failure, sometimes requiring haemodialysis. 
Z eksenatidom so bili zabeleženi občasni primeri spremenjenega delovanja ledvic, vključno z zvišanjem kreatinina v serumu, okvaro ledvic, poslabšanjem kronične odpovedi ledvic in akutno odpovedjo ledvic, z občasno potrebo po hemodializi.
In postmarketing experiences, cases with injection site abscesses and cellulitis have been reported. 
V obdobju trženja zdravila so poročali o abscesih in celulitisu na mestu injiciranja.
• WITHOUT twisting the knob, ROTATE the pen every few taps. 
• Peresnik vsakih nekaj udarcev OBRNITE, NE DA BI pri tem zasukali gumb.
Clinical studies with prolonged-release exenatide formulations have indicated improved beta-cell function, using measures such as the homeostasis model assessments (HOMA-B). 
Klinične študije z eksenatidom v obliki s podaljšanim sproščanjem so pokazale izboljšano delovanje beta celic, kar je bilo dokazano z metodami kot je ocenjevanje homeostaznega modela (HOMA-B).
The improvement in fasting plasma glucose concentrations was durable through 52 weeks. 
Izboljšanje v koncentraciji glukoze v plazmi na tešče je trajalo vseh 52 tednov.
DO NOT try to recap or reuse the needle. 
NE POSKUŠAJTE ponovno namestiti pokrovčka na iglo ali igle uporabiti znova.
After discontinuation, the effect of prolonged-release exenatide may continue as plasma levels of exenatide decline over 10 weeks. 
Po ukinitvi zdravljenja se lahko učinek eksenatida v obliki s podaljšanim sproščanjem nadaljuje, saj koncentracija eksenatida v plazmi pada naslednjih 10 tednov.
The powder is white to off-white and the solvent is a clear, colourless to pale yellow to pale brown solution. 
Prašek je bel do belkast in vehikel je bistra, brezbarvna do bledo rumena oziroma do bledo rjava raztopina.
Patients on pioglitazone gained weight (Table 6). 
Bolniki na pioglitazonu so pridobili na telesni masi (Preglednica 6).
The medicine is injected into your skin (subcutaneously). 
Zdravilo se injicira pod kožo (subkutano).
The solvent should only be used if it is clear and free of particulate matter. 
Vehikel se lahko uporabi le v primeru, ko je bister in ne vsebuje delcev.
- The other ingredients are: - In the powder: poly (D,L-lactide-co-glycolide) and sucrose. 
- Druge sestavine zdravila so: - V prašku: poli (D,L-laktid koglikolid) in saharoza.
The pen must be removed from the refrigerator for at least 15 minutes prior to injection. 
Peresnik je treba vsaj 15 minut pred injiciranjem vzeti iz hladilnika.
Increased heart rate 
Zvišan srčni utrip
INSTRUCTIONS FOR THE USER Read these instructions carefully before use 
Pred uporabo natančno preberite ta navodila
Following weekly administration of 2 mg prolonged-release exenatide, mean exenatide concentrations exceeded minimal efficacious concentrations (~ 50 pg/ml) in 2 weeks with gradual increase in the average plasma exenatide concentration over 6 to 7 weeks. 
Ob tedenskem dajanju 2 mg eksenatida v obliki s podaljšanim sproščanjem je povprečna koncentracija eksenatida v dveh tednih presegla minimalno učinkovito koncentracijo (~ 50 pg/ml), s postopnim povečevanjem povprečne plazemske koncentracije eksenatida preko 6 do 7 tednov.
Follow the “Instructions for the User” provided in the carton to inject Bydureon 
Sledite “Navodilom za uporabnika”, ki se nahajajo v škatli, za injiciranje zdravila Bydureon.
Needle Top of pen 
Igla Vrh peresnika
Rate based on twelve prolonged-release exenatide completed long-term efficacy and safety studies n=2868 total (patients on sulphonylurea n=1002). 
Pogostnost na podlagi dvanajstih dokončanih dolgoročnih študij učinkovitosti in varnosti eksenatida v obliki s podaljšanim sproščanjem, n skupaj = 2868, (število bolnikov na sulfonilsečnini n = 1002).
With your thumb, push down the plunger until it stops and hold your thumb in place. 
S palcem pritisnite bat navzdol, dokler se ne ustavi in palec držite na mestu.
The need for additional antihyperglycaemic medication was reduced by 33% % with the prolongedrelease exenatide group (exposure-adjusted incidence of 10.5 per 100 pt-year) compared to the placebo group (exposure-adjusted incidence of 15.7 per 100 pt-year). 
Potreba po dodatnem antihiperglikemičnem zdravilu se je v skupini z eksenatidom v obliki s podaljšanim sproščanjem zmanjšala za 33 % (za izpostavljenost korigirana pojavnost 10,5 na 100 bolnikov-let) v primerjavi s placebom (za izpostavljenost korigirana pojavnost 15,7 na 100 bolnikov-let).
You should inject this medicine into the skin (subcutaneous injection) of your stomach area (abdomen), upper leg (thigh), or the back of your upper arm. Do not inject into a vein or muscle. 
To zdravilo si injicirajte v kožo (subkutana injekcija) področja trebuha (abdomna), zgornjega dela noge (stegno) ali zadnjega dela nadlakti.
Remove the syringe. 
Odstranite injekcijsko brizgo.
A. Let your pen come to room temperature. 
A. Pustite, da se peresnik ogreje na sobno temperaturo.
If you see white medicine on the sides, bottom or top of the pen window, the medicine is NOT mixed well. 
Če vidite belo zdravilo ob straneh, na dnu ali na vrhu okenca peresnika, zdravilo NI dobro premešano.
If a different glucose-lowering treatment is started after the discontinuation of prolonged-release exenatide, consideration should be given to the prolonged release of the product (see section 5.2). 
Če se po končanem zdravljenju z eksenatidom v obliki s podaljšanim sproščanjem začne zdravljenje z drugim antidiabetikom, je potrebno upoštevati podaljšan učinek tega zdravila (glejte poglavje 5.2).
Most episodes of nausea were mild to moderate, associated with the initiation of treatment and decreased over time. 
Večinoma je bila navzea blaga do zmerna, povezana z uvedbo zdravila ter se je sčasoma zmanjšala.
Do not remove the needle cover yet. 
Pokrova igle za zdaj še ne odstranite.
Each dose should be administered in the abdomen, thigh, or the back of the upper arm as a subcutaneous injection immediately after the medicinal product is fully mixed. 
Vsak odmerek moramo kot subkutano injekcijo dati v trebuh, stegno ali nadlaket takoj, ko je zdravilo popolnoma premešano.
In the 4 comparator-controlled studies, this reduction in body weight was seen in patients treated with prolonged-release exenatide irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction of -2.9 kg to -5.2 kg with nausea versus -2.2 kg to -2.9 kg without nausea). 
V 4 s primerjalnimi zdravili kontroliranih študijah je bilo to znižanje telesne mase pri bolnikih, ki so se zdravili z eksenatidom v obliki s podaljšanim sproščanjem, neodvisno od pojava navzee, bilo pa je večje pri skupini z navzeo (povprečno znižanje -2,9 kg do -5,2 kg z navzeo proti -2,2 kg do -2,9 kg brez navzee).
Clinical experience in patients with moderate renal impairment (creatinine clearance 30 to 50 ml/min) is limited (see section 5.2). 
Kliničnih izkušenj pri bolnikih z zmerno okvaro ledvic (očistek kreatinina 30 do 50 ml/min) je malo (glejte poglavje 5.2).
The reductions in body weight were sustained at Week 52. 
Zmanjšanje telesne mase je bilo po 52 tednih ohranjeno.
Do not throw the container in your household waste. 
Vsebnika ne odvrzite med gospodinjske odpadke.
Use your thumb to remove the green cap. 
S palcem odstranite zelen pokrovček.
Vial connector 
viala povezovalec viale (vial connector)
In two studies prolonged-release exenatide 2 mg once weekly has been compared to immediate-release exenatide 5 mcg given twice daily for 4 weeks followed by immediate-release exenatide 10 mcg given twice daily. 
Dve študiji z eksenatidom v obliki s podaljšanim sproščanjem 2 mg enkrat tedensko sta bili primerjani z eksenatidom v obliki s takojšnim sproščanjem 5 µg dvakrat dnevno 4 tedne, čemur je sledil eksenatid v obliki s takojšnim sproščanjem 10 µg dvakrat dnevno.
• Read the Package Leaflet carefully. 
• Natančno preberite navodilo za uporabo.
With the other hand, twist the orange connector to remove. 
Z drugo roko odvijte oranžni povezovalec in ga odstranite.
Now, hold the vial so the syringe is pointing up. 
Sedaj primite vialo tako, da injekcijska brizga gleda gor.
Population pharmacokinetic analysis of renal impaired patients receiving 2 mg prolonged-release exenatide indicate that there may be an increase in systemic exposure of approximately 74% and 23% (median prediction in each group) in moderate (N = 10) and mild (N = 56) renal impaired patients, respectively as compared to normal (N = 84) renal function patients. 
Populacijska farmakokinetična analiza bolnikov z okvaro ledvic, ki so prejemali 2 mg eksenatida v obliki s podaljšanim sproščanjem, kaže, da lahko pride do zvišane sistemske izpostavljenosti pri približno 74 % in 23 % (predvideni srednji vrednosti v vsaki skupini) bolnikih z zmerno (n = 10) in blago (n = 56) okvaro ledvic, v primerjavi z bolniki z normalnim (n = 84) delovanjem ledvic.
Use a new injection needle for each injection and dispose of it safely after each use as instructed by your doctor or diabetes nurse. 
Za vsako injiciranje uporabite novo injekcijsko iglo in jo po vsaki uporabi varno zavrzite, kot vam je naročil zdravnik ali medicinska sestra v diabetološki ambulanti.
The results of two studies with Bydureon BCise and six long-term clinical studies of prolonged-release exenatide are presented below; these studies comprised 1766 subjects (556 treated with Bydureon BCise), 53% men and 47% women, 304 subjects (17%) were ≥ 65 years of age. 
Te študije so vključevale 1766 preiskovancev (556 zdravljenih z zdravilom Bydureon BCise), 53 % moških in 47 % žensk; 304 osebe (17 %) so bile stare ≥ 65 let.
Furthermore, in the clinical studies, patients on a sulphonylurea combination with mild renal impairment had an increased incidence of hypoglycaemia compared to patients with normal renal function. 
V kliničnih študijah pri bolnikih z blago okvaro ledvic, ki so jemali kombinacijo s sulfonilsečnino, je bila incidenca hipoglikemije večja v primerjavi z bolniki z normalnim delovanjem ledvic.
Prolonged-release exenatide 2 mg + Insulin glargine 
2 mg eksenatida v obliki s podaljšanim sproščanjem + insulin glargin
No pharmacokinetics study of prolonged-release exenatide has been conducted in the paediatric population. 
Pri pediatrični populaciji niso izvedli nobenih farmakokinetičnih študij z eksenatidom v obliki s podaljšanim sproščanjem.